Long acting GLP-1 receptor agonist (injectable)
Albiglutide 100 mg injection every 4 weeks
ALBI_SC_100MG_Q4W
Related
- All doses pooled: Albiglutide injection
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.86 (0.57 to 5.42) | 0.26 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.53 (2.15 to 9.08) | 0.29 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.42 (3.81 to 24.13) | 0.15 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.60 (0.60 to 3.97) | 0.50 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.11 (0.08 to 7.93) | 0.59 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.06 to 15.76) | 0.46 |